SoundHealth launched a new feature in its AI-powered health care app that will give users personalized allergy forecasts to ...

FDA officials say this is the first epinephrine product for anaphylaxis that is not administered with a needle.

The device could upend treatment for the 33 million to 45 million Americans with severe allergies to food and other triggers.

We came across a bullish thesis on ARS Pharmaceuticals (SPRY) on Value Degen’s Substack by Unemployed Value Degen. In this ...

A nasal spray developed ... Research shows the spray, recently approved in the EU and US, is just as effective at stopping ...

The FDA has approved a nasal spray, called neffy, to treat serious allergic reactions in adults and children who weigh at ...

ARS Pharmaceuticals' neffy, a needle-free nasal spray for allergies, receives FDA approval, driving stock price up 120%. Read ...

The FDA has approved AstraZeneca's Fasenra for eosinophilic granulomatosis with polyangiitis based on Phase 3 MANDARA trial ...

The US Food and Drug Administration (FDA) has approved the targeted interleukin (IL)-13 inhibitor lebrikizumab (Ebglyss) for ...

The FDA broadened dupilumab's (Dupixent) approval as an add-on maintenance treatment for chronic rhinosinusitis with nasal ...

The FDA recently approved the first needle-free epinephrine product (neffy), an alternative to injectable epinephrine (EpiPen ...